Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Kerry A. Whalen, Kavya Rakhra, Naveen K. Mehta, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 85
Development of NK cell-based cancer immunotherapies through receptor engineering
Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 4, pp. 315-331
Open Access | Times Cited: 68
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Beibei Zhang, Mengzhe Yang, Weimin Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 30
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
Faryal Munir, Viney Hardit, Irtiza Sheikh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10095-10095
Open Access | Times Cited: 22
From mechanism to therapy: the journey of CD24 in cancer
Kai Zhao, Caifeng Wu, Xiangjun Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
Anna Seller, Christian M. Tegeler, J. Mauermann, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4126-4126
Open Access | Times Cited: 5
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
H. In, Minkyoung Park, H.-K. Lee, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 16-16
Open Access
γδT cells, a key subset of T cell for cancer immunotherapy
Jianzhen Lv, Zheng Liu, Xingye Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
Kerry A. Whalen, Cathérine Henry, Naveen K. Mehta, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e008987-e008987
Open Access
Contemporary Approaches to Immunotherapy of Solid Tumors
A. V. Kuznetsova, Ksenia А. Glukhova, О. П. Попова, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2270-2270
Open Access | Times Cited: 3
23ME-01473, an Fc Effector–Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell–Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation
Joel S. Benjamin, Abigail Jarret, Shashank Bharill, et al.
Cancer Research Communications (2025) Vol. 5, Iss. 3, pp. 476-495
Open Access
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells
Caterina Marangio, Nadia Domenica Milito, Erisa Putro, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells
Kim Anh Giang, Thorstein Boxaspen, Yumei Diao, et al.
New Biotechnology (2023) Vol. 77, pp. 139-148
Open Access | Times Cited: 6
Heterogeneity of modulatory immune microenvironment in bladder cancer
Enas El Saftawy, Basma Emad Aboulhoda, Mansour A. Alghamdi, et al.
Tissue and Cell (2024) Vol. 93, pp. 102679-102679
Closed Access | Times Cited: 1
Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys
Peter B. Rupert, Matthew Buerger, Emily J. Girard, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28583-e28583
Open Access
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
Mohadeseh Mohammad Taheri, Fatemeh Javan, Mohadeseh Poudineh, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46
Min Hwa Shin, Eunha Oh, Dohsik Minn
Immune Network (2024) Vol. 24, Iss. 5
Open Access
Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells
Lucía Paniagua‐Herranz, Cristina Díaz‐Tejeiro, Adrián Sanvicente, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top